Navellier & Associates’s iShares Biotechnology ETF IBB Stock Holding History

Navellier & Associates’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$531K	Buy	+2,794	New	+$480K	0.04%	239
2025 Q4	–	Sell	-3,572	Closed	-$516K	–	361
2025 Q3	$516K	Buy	+3,572	New	+$488K	0.05%	256
2024 Q3	–	Sell	-3,565	Closed	-$489K	–	336
2024 Q2	$489K	Buy	+3,565	New	+$476K	0.06%	244
2021 Q4	–	Sell	-2,316	Closed	-$374K	–	334
2021 Q3	$374K	Buy	+2,316	New	+$390K	0.06%	233
2021 Q2	–	Sell	-3,303	Closed	-$497K	–	323
2021 Q1	$497K	Buy	+3,303	New	+$525K	0.09%	179
2020 Q1	–	Sell	-17,677	Closed	-$2.13M	–	262
2019 Q4	$2.13M	Buy	+17,677	New	+$1.97M	0.34%	84
2018 Q4	–	Sell	-62,187	Closed	-$7.58M	–	265
2018 Q3	$7.58M	Buy	+62,187	New	+$7.32M	0.98%	26
2018 Q1	–	Sell	-6,750	Closed	-$721K	–	318
2017 Q4	$721K	Buy	+6,750	New	+$722K	0.13%	157
2017 Q1	–	Sell	-40,095	Closed	-$3.55M	–	297
2016 Q4	$3.55M	Buy	40,095 +6,366	+19%	+$579K	0.59%	73
2016 Q3	$3.25M	Buy	+33,729	New	+$3.21M	0.47%	72
2015 Q3	–	Sell	-12,465	Closed	-$1.53M	–	345
2015 Q2	$1.53M	Buy	12,465 +3,051	+32%	+$365K	0.13%	85
2015 Q1	$1.08M	Buy	+9,414	New	+$1.04M	0.1%	105

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Navellier & Associates's IBB Position: Q2 2026 in Review

Navellier & Associates opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 2,794 shares worth $531K. The stake represents 0.04% of the portfolio and ranks #239 among its holdings. This is a return to the name: Navellier & Associates previously reported a position in IBB as recently as Q3 2025.

Navellier & Associates first reported a position in IBB in Q1 2015 and has held it in 12 quarters since. The position peaked at $7.58M in Q3 2018. 957 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Navellier & Associates held 2,794 shares of iShares Biotechnology ETF worth $531K as of Q2 2026.
iShares Biotechnology ETF was a new Navellier & Associates position in Q2 2026.
iShares Biotechnology ETF made up 0.04% of Navellier & Associates's portfolio in Q2 2026, its #239 holding.
Navellier & Associates first reported a position in iShares Biotechnology ETF in Q1 2015 and has held it in 12 quarters since.
Navellier & Associates's iShares Biotechnology ETF position peaked at $7.58M in Q3 2018.
957 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Navellier & Associates's 13F filing for Q2 2026, filed 4 Aug 2026.